{"id":"hlx04-o","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thromboembolic events"},{"rate":null,"effect":"Gastrointestinal perforation"}]},"_chembl":{"chemblId":"CHEMBL2105909","moleculeType":"Small molecule","molecularWeight":"330.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HLX04-O is a bevacizumab biosimilar candidate developed by Shanghai Henlius Biotech. It targets VEGF, a key signaling molecule that promotes the formation of new blood vessels that tumors depend on for growth and metastasis. By neutralizing VEGF, the drug inhibits angiogenesis, starving tumors of oxygen and nutrients while also normalizing the tumor vasculature to improve drug delivery.","oneSentence":"HLX04-O is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:44.976Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Non-small cell lung cancer"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT05003245","phase":"PHASE3","title":"Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-11-01","conditions":"Age Related Macular Degeneration","enrollment":407},{"nctId":"NCT04740671","phase":"PHASE3","title":"A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-07-01","conditions":"Age Related Macular Degeneration","enrollment":410},{"nctId":"NCT04993352","phase":"PHASE1, PHASE2","title":"Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-07-15","conditions":"Age Related Macular Degeneration","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HLX04-O","genericName":"HLX04-O","companyName":"Shanghai Henlius Biotech","companyId":"shanghai-henlius-biotech","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HLX04-O is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells. Used for Metastatic colorectal cancer, Non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}